Conversely, in MLL-driven AML and in JAK2V617F-positive MPN, targeting JMJD2C reduces leukemogenicity by increasing differentiation, promoting cell cycle arrest and enhancing apoptosis [10, 12, 13]. Here, KMT2A is linked to myeloproliferative neoplasm.